RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Fla., praised news that President Donald Trump will reinstate service members expelled for refusing to take the COVID-19 ...

August 26: Moderna Inc (MRNA.O) said on Wednesday it has withheld supply of about 1.63 million doses of its COVID-19 vaccine in Japan after a report of contamination of vials with particulate matter, ...

At the time of writing, Moderna had not as yet responded to enquiries about its intentions surrounding its Covid-19 vaccine, Spikevax. Vertex's gene-editing therapy for sickle cell disease ...

Shares of vaccine maker Moderna fell Wednesday as Goldman Sachs lowered its rating after the biotech’s second cut to product ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on Moderna (MRNA – Research Report), with a price target ...

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance ...

Researchers at the University of Oxford and their collaborators, including the Serum Institute of India, have developed an innovative method to identify falsified vaccines without opening the vaccine ...

In these cases, the label on the vaccine vial had also been falsified. The Vaccine Identify Evaluation (VIE) Collaboration are developing novel tests for detecting falsified vaccines in supply chains.